Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (  25 years) of the Phase III SBII:2pre Trial

Ekholm Maria; Bendahl Par-Ola; Ferno Marten; Nordenskjold Bo; Stal Olle; Ryden Lisa

首页> 外文期刊>Journal of Clinical Oncology >Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up ( 25 years) of the Phase III SBII:2pre Trial

【24h】

Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up ( 25 years) of the Phase III SBII:2pre Trial

机译：与无系统治疗相比，两年的辅助用他莫昔芬在绝经前患有原发性乳腺癌的患者中具有生存优势：III期SBII：2pre试验的长期随访（> 25年）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2016年第19期|共10页
作者
Ekholm Maria; Bendahl Par-Ola; Ferno Marten; Nordenskjold Bo; Stal Olle; Ryden Lisa;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up ( 25 years) of the Phase III SBII:2pre Trial [J] . Ekholm Maria, Bendahl Par-Ola, Ferno Marten, Journal of Clinical Oncology . 2016,第19期

机译：与无系统治疗相比，两年的辅助用他莫昔芬在绝经前患有原发性乳腺癌的患者中具有生存优势：III期SBII：2pre试验的长期随访（> 25年）
2. Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1-4 years: N-SAS BC 03. [J] . Ohsumi S, Shimozuma K, Ohashi Y, Breast cancer research and treatment. . 2011,第1期

机译：乳腺癌患者手术后的健康相关生活质量和心理困扰，该研究在一项三期随机试验中比较了他莫昔芬的持续性和他莫昔芬辅助治疗后1-4年改用阿那曲唑的疗效：N-SAS BC 03。
3. Health-related quality of life and psychological distress of breast cancer patients after surgery during a phase III randomized trial comparing continuation of tamoxifen with switching to anastrozole after adjuvant tamoxifen for 1–4 years: N-SAS BC 03 [J] . Shozo Ohsumi, Kojiro Shimozuma, Yasuo Ohashi, Breast Cancer Research and Treatment . 2011,第1期

机译：乳腺癌患者手术后的健康相关生活质量和心理困扰，该研究在一项三期随机试验中比较了他莫昔芬的持续性和他莫昔芬辅助后转用阿那曲唑治疗1-4年：N-SAS BC 03
4. Results of treatment of the patients with II~(nd)-III~(rd) st. breast cancer by combination of low level laer therapy (LLLT) and surgery (10-year experience) [C] . V.A.Mikhailov, I.N.Densiov, G.A.Frank, Conference on Laser Florence'99: A Window on the Laser Medicine World 28-31 October 1999 Florence, Italy . 1999

机译：II〜（nd）-III〜（rd）st患者的治疗结果。低水平激光疗法（LLLT）和手术相结合的乳腺癌（10年经验）
5. Nutritional Risk in the Cancer Patient 65 and Older Undergoing Systemic Treatment via Phase I Clinical Trials [D] . Williams, Anna Cathy. 2019

机译：癌症患者65岁及以上经受I期临床试验的营养风险
6. Updated Survival Analysis after a Median Follow-up of 12 Years of an Anthracycline-Containing Adjuvant Prospective Multicentre Randomised Phase III Trial on Dose-Dense Chemotherapy in Primary Node-Positive High-Risk Breast Cancer Patients [O] . Mattea Reinisch, Oleg Gluz, Beyhan Ataseven, 2019

机译：对原发于淋巴结阳性高风险的乳腺癌患者进行剂量密集型化疗的含蒽环类辅助佐治性前瞻性多中心随机III期试验的中位随访12年后的最新生存分析
7. Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial [O] . Ekholm, Maria, Bendahl, Par-Ola, Ferno, Marten, 2016

机译：与无系统治疗相比，两年的他莫昔芬辅助治疗可为绝经前原发性乳腺癌患者提供生存优势：III期SBII：2pre试验的长期随访（> 25年）

Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up ( 25 years) of the Phase III SBII:2pre Trial

摘要

著录项

相似文献

相关主题

期刊订阅